- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT05847790
Suivi de grossesse à distance pour améliorer l'accès (REACTIVE)
Surveillance à distance de la grossesse pour améliorer l'accès : l'essai REACTIVE
The goal of this clinical trial is to determine the effectiveness of remote nonstress test (NST) compared to in-clinic NSTs in improving fetal testing completion rates. Participants will be randomized to either in-clinic NSTs or use of an FDA-approved remote monitoring belt for their pregnancy monitoring.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, États-Unis, 19104
- University of Pennsylvania
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Enfant
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Singleton pregnancy
- Gestational age between 30 weeks 0 days and 35 weeks 6 days
- Pregnant patients who have clinical indication for fetal surveillance with NSTs (based on UPHS Health System clinical guidelines for antenatal monitoring)
- Able to provide written consent
- English speaking
Exclusion Criteria:
- Multiple gestations
- Maternal pre-gravid BMI greater than 45kg/m2
- Presence of an implanted pacemaker or defibrillator
- Active abdominal skin infection
- A known amniotic fluid index (AFI) less than 5cm or greater than 25cm on the most recent ultrasound (if available) prior to randomization
- Delivery is planned within 2 weeks of potential randomization
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Diagnostique
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: NST à distance
|
INVU monitoring belt used for remote NSTs |
|
Comparateur actif: NST en clinique - Norme de soins
|
In-clinic NSTs - standard of care |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Fetal Testing Completion Rate
Délai: from 32 weeks gestational age to delivery, average of 10 weeks after enrollment.
|
Percentage of recommended antenatal testing sessions successfully completed, defined as a clinically interpreted test performed. Calculated for each participant as: number of NST visits completed divided by number of NST visits expected × 100. |
from 32 weeks gestational age to delivery, average of 10 weeks after enrollment.
|
|
Fetal Testing Completion Rate in Black Versus Non-Black Subjects
Délai: from 32 weeks gestational age to delivery, average of 10 weeks after enrollment.
|
Comparison between Black and non-Black subjects' percentage of recommended antenatal testing sessions that were successfully completed as defined as a clinically interpreted test was performed. Calculated as the number of NST visits completed divided by the number of NST visits expected per participant × 100. |
from 32 weeks gestational age to delivery, average of 10 weeks after enrollment.
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Fetal Monitoring Outcomes: Number of Visits to the Antenatal Testing Unit
Délai: from 32 weeks gestational age to delivery, average of 10 weeks after enrollment.
|
Count of visits to the office for in-person monitoring |
from 32 weeks gestational age to delivery, average of 10 weeks after enrollment.
|
|
Fetal Monitoring Outcomes: Percentage of Non-Stress Test Sessions Requiring Provider-Recommended Prolonged Monitoring
Délai: From randomization until delivery.
|
For each participant, the percentage of all NST sessions requiring prolonged monitoring (>40 minutes) was calculated. The median participant-level percentage is reported. |
From randomization until delivery.
|
|
Fetal Monitoring Outcomes: Average Duration of Non-Stress Test Monitoring Sessions
Délai: From randomization until delivery.
|
Mean duration of NST monitoring sessions across all NSTs completed by each participant from randomization to delivery. Participant-level means were calculated and summarized by study arm. |
From randomization until delivery.
|
|
Fetal Monitoring Outcomes: Non-reactive NST Rate
Délai: From randomization until delivery
|
Percentage of NSTs that were non-reactive among all NSTs completed for each participant. |
From randomization until delivery
|
|
Fetal Monitoring Outcomes: Percentage of NSTs Resulting in Biophysical Profile Evaluation
Délai: From randomization until delivery.
|
Percentage of completed NSTs followed by biophysical profile assessment. |
From randomization until delivery.
|
|
Fetal Monitoring Outcomes: Number of Participants With ≥1 Obstetrical Triage Visit
Délai: From randomization to delivery
|
Number of Participants With ≥1 Obstetrical Triage Visit |
From randomization to delivery
|
|
Fetal Monitoring Outcomes: Number of Participants Who Had Any Triage Visit Directly Related to a Fetal Monitoring Visit
Délai: From randomization to delivery
|
Number of participants who underwent at least one obstetrical triage evaluation directly related to a fetal monitoring visit, during the study period from randomization until delivery. |
From randomization to delivery
|
|
Fetal Monitoring Outcomes: Number of Participants Recommended for Delivery Based on Findings on Fetal Monitoring Result
Délai: From randomization to delivery
|
Count of the number of subjects in each arm who receive a recommendation for delivery based on the findings of the fetal monitoring results. |
From randomization to delivery
|
|
Fetal Monitoring Outcomes: Percentage of NSTs Not Completed Within the Prescribed Window
Délai: from 32 weeks gestational age to delivery, average of 10 weeks after enrollment.
|
Percentage of NSTs which occur outside of prescribed window, for example, if a weekly testing regimen is prescribed, an appointment 8 or more days following the last one would count as 1 missed calendar window. |
from 32 weeks gestational age to delivery, average of 10 weeks after enrollment.
|
|
Obstetrics Outcomes: Gestational Age at Delivery
Délai: time of delivery
|
gestational age at time of delivery |
time of delivery
|
|
Obstetrics Outcomes: Number of Participants With Preterm Delivery
Délai: time of delivery
|
preterm delivery is defined as less than 37 weeks gestational age |
time of delivery
|
|
Obstetrics Outcomes: Mode of Delivery
Délai: time of delivery
|
categorized as vaginal or cesarean |
time of delivery
|
|
Obstetrics Outcomes: Number of Participants With an Indication for Labor Induction
Délai: time of labor induction
|
in subjects who have labor induction, indication for inducing labor |
time of labor induction
|
|
Obstetrics Outcomes: Number of Participants With an Indication for Cesarean Section
Délai: time of delivery
|
in subjects who have a cesarean section delivery, indication for cesarean section |
time of delivery
|
|
Obstetrics Outcomes: Number of Participants With Composite Neonatal Morbidity
Délai: from delivery to 6 weeks post-delivery
|
Number of participants whose neonate experienced at least one component of the composite neonatal morbidity outcome, defined as severe respiratory distress, neonatal resuscitation outside the delivery room, or neonatal death. |
from delivery to 6 weeks post-delivery
|
|
Obstetrics Outcomes: Neonatal Cord Blood pH
Délai: time of delivery
|
time of delivery
|
|
|
Obstetrics Outcomes: Apgar Scores
Délai: one and five minutes after delivery
|
Apgar score at 1 and 5 minutes after delivery. Scores range from 0 to 10, with higher scores indicating better neonatal condition |
one and five minutes after delivery
|
|
Obstetrics Outcomes: Number of Participants With an Admission to the Neonatal Intensive Care Unit
Délai: from delivery to 6 weeks post-delivery
|
from delivery to 6 weeks post-delivery
|
|
|
Obstetrics Outcomes: Number of Participants Who Had an Admission to the Neonatal Intensive Care Unit for Greater Than 48 Hours
Délai: from delivery to 6 weeks post-delivery
|
from delivery to 6 weeks post-delivery
|
|
|
Obstetrics Outcomes: Maternal Length of Hospital Stay
Délai: Delivery hospitalization
|
Length of maternal hospitalization associated with the delivery admission, measured from hospital admission for delivery through maternal discharge. |
Delivery hospitalization
|
|
Obstetrics Outcomes: Neonatal Length of Hospital Stay
Délai: Birth hospitalization
|
Length of neonatal hospitalization from birth through hospital discharge. |
Birth hospitalization
|
|
Cost-effectiveness Outcomes: Productivity Loss Due to Antenatal Testing and Monitoring
Délai: From randomization until delivery (approximately 10 weeks on average)
|
Productivity loss was assessed by summing the number of days of work missed reported by participants across the two study productivity assessments. The reported value represents the total number of work days missed during the study period for each participant. |
From randomization until delivery (approximately 10 weeks on average)
|
|
Cost-effectiveness Outcomes: Total Societal Perspective Cost
Délai: Randomization through delivery
|
Total societal perspective cost per participant, calculated as the sum of direct healthcare costs, informal healthcare costs, and productivity costs incurred from randomization through delivery. Costs are reported in U.S. dollars (USD). The societal perspective includes costs related to antenatal testing, delivery hospitalization, neonatal care, triage visits, antepartum admissions, productivity losses, caregiving, and transportation. |
Randomization through delivery
|
|
Implementation Outcomes: Theory-informed Acceptability Questionnaire
Délai: at time of delivery
|
Participant acceptability of the assigned fetal monitoring strategy was assessed using an 8-item Theory-Informed Acceptability Questionnaire (TFA). Total scores range from 8 to 40, with higher scores indicating greater acceptability of the monitoring approach. |
at time of delivery
|
Collaborateurs et enquêteurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 852291
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .